Jazz Pharmaceuticals (JAZZ)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$227.32-3.13%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
Research Workspace
Put JAZZ beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Revenue growth of at least 6% per year: Revenue growth: 10.38%.
View ThesisRevenue growth is accelerating — up about 13% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on the balance sheet, market reaction to earnings.
View ManagementExpectations look high — the market is pricing in about 19% growth a year, above the roughly 6% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskJazz Pharmaceuticals needs Ziihera to keep compounding to justify the price. Revenue growth is slowing, dropping from 19% to 10% year over year. The company recently beat earnings estimates by 25%. It trades at 24 times earnings versus a 14 times peer median. The market is pricing in more growth than we forecast. A guidance cut would hit credibility and the stock hard. Peer multiples imply a price about 20% below where it trades. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-05. JAZZ is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 22 analysts currently covering JAZZ (as of Nov 2026).
Based on 13 Wall Street analysts offering 12-month price targets for JAZZ in the last 4 months.
Continue this research
Compare JAZZ with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| JAZZ Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-11-05. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put JAZZ next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase revenue growth
Official guidance confirms revenue growth trajectory.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-05. EPS is implied from price ÷ P/E. Not investment advice.
Current $227.32
The last 12 months of price, then the range of analyst 12-month targets from today’s $227.32.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Increase revenue growth
Record revenue and raised outlook confirm growth trajectory.
Threatens: Improve operating income
Significant EPS miss signals cost pressure despite revenue beat.
Advances: Advance pipeline and regulatory activities
Significant investment in epilepsy aligns with pipeline advancement.
Advances: Advance pipeline and regulatory activities
Rare-disease push aligns with advancing pipeline objectives.
Advances: Enhance cash from operations
Debt upgrade indicates improved cash flow potential.
Advances: Advance pipeline and regulatory activities
Ziihera's success enhances pipeline and regulatory activities.
Advances: Advance pipeline and regulatory activities
Positive trial results support pipeline advancement.
